JY
SMMT icon

Jeff Yass’s Summit Therapeutics SMMT Stock Holding History

Jeff Yass’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Sell
1,109,200
-130,100
-10% -$2.31M ﹤0.01% 2698
2026
Q1 		$23.5M Sell
1,239,300
-563,400
-31% -$9.11M ﹤0.01% 2026
2025
Q4 		$31.5M Buy
1,802,700
+411,000
+30% +$7.73M ﹤0.01% 1771
2025
Q3 		$28.8M Buy
1,391,700
+345,400
+33% +$8.38M ﹤0.01% 1838
2025
Q2 		$22.3M Buy
1,046,300
+296,200
+39% +$6.75M ﹤0.01% 1898
2025
Q1 		$14.5M Buy
750,100
+443,300
+144% +$8.89M ﹤0.01% 2080
2024
Q4 		$5.48M Sell
306,800
-304,300
-50% -$5.9M ﹤0.01% 3455
2024
Q3 		$13.4M Buy
611,100
+475,000
+349% +$6.64M ﹤0.01% 2249
2024
Q2 		$1.06M Buy
136,100
+114,800
+539% +$620K ﹤0.01% 6432
2024
Q1 		$88.2K Buy
+21,300
New +$84.7K ﹤0.01% 11287
2023
Q4 		– Sell
-13,300
Closed -$24.9K – 13230
2023
Q3 		$24.9K Sell
13,300
-1,000
-7% -$1.91K ﹤0.01% 11542
2023
Q2 		$35.9K Sell
14,300
-210,100
-94% -$383K ﹤0.01% 11460
2023
Q1 		$393K Sell
224,400
-457,400
-67% -$1.25M ﹤0.01% 9138
2022
Q4 		$2.9M Buy
+681,800
New +$1.24M ﹤0.01% 4072

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jeff Yass's SMMT Position: Q2 2026 in Review

Jeff Yass reduced its Summit Therapeutics (SMMT) stake by 14% in Q2 2026, selling an estimated $1.46M and leaving 521,339 shares worth $7.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3847.

Jeff Yass first reported a position in SMMT in Q3 2017 and has held it in 23 quarters since. The position peaked at $11.5M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Jeff Yass held 521,339 shares of Summit Therapeutics worth $7.6M as of Q2 2026.
  • Jeff Yass sold 82,594 Summit Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Summit Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #3847 holding.
  • Jeff Yass first reported a position in Summit Therapeutics in Q3 2017 and has held it in 23 quarters since.
  • Jeff Yass's Summit Therapeutics position peaked at $11.5M in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.